Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | high-affinity cgmp-specific 35-cyclic phosphodiesterase | 0.8608 | 0.5 | 0.5 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.8608 | 0.5 | 0.5 |
Plasmodium falciparum | 3',5'-cyclic nucleotide phosphodiesterase, putative | 0.8608 | 0.5 | 0.5 |
Echinococcus multilocularis | high affinity cgmp specific 3' 5' cyclic | 0.8608 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | Neurotoxicity in albino CF-1 mouse assessed as minimum motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test | ChEMBL. | 22082834 | |
Activity (ADMET) | Neurotoxicity in albino CF-1 mouse assessed as minimum motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test | ChEMBL. | 22082834 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.